Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.
Also called NCT07180745
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Badr University
- Registry
-
NCT07180745
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07180745. Randomized; no masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2026-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
- Condition
- Non-alcoholic Fatty Liver Disease NAFLD
- Condition
- Non-alcoholic Steatohepatitis NASH
- Intervention (Drug)
- Pioglitazone (PIO)
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Statin (Atorvastatin)
- Intervention (Drug)
- Empagliflozin plus Statin (Atorvastatin)
- Intervention (Drug)
- Pioglitazone plus Atorvastatin
- Lead sponsor
- Badr University
Record details
- Record id
cardio:ct-nct07180745- Content hash
2056aa212daba53230a9e33a7c108486ffb886d5c453b43b105dc96972470dad